Clinical trials of antithrombotics - TrialResults-center.org

Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Major bleeding
Group by... in first in second in third	Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Global trial result Main results All results All result tag NCT results	Numeric bar chart forest plot medians
acute coronary syndrome
apixaban
APPRAISE-1 (10mg od), 2009 NCT	apixaban	placebo			Low risk of bias	negative
APPRAISE-1 (2.5 mg bid), 2009 NCT	apixaban	placebo			Low risk of bias	negative
APPRAISE 2, 2011 NCT	apixaban	placebo			Low risk of bias	negative
argatroban
ARGAMI-2, 1998	Argatroban	heparin				-
aspirin
ATACS-pilot, 1990	aspirin	control				negative
VA-pilot	aspirin	placebo				negative
VA-main, 1983	aspirin	placebo			Low risk of bias	suggesting
RISC, 1990	aspirin	placebo			Low risk of bias	suggesting
ALDUSA-pilot	aspirin	placebo				negative
Théroux, 1988	aspirin	placebo			Low risk of bias	suggesting
Canadian (Aspirin vs PBO), 1985	aspirin	placebo			Low risk of bias	-
Canadian (Aspirin + sulfinpyrazone), 1985	aspirin + sulfinpyrazone	placebo			Low risk of bias	negative
atopaxar
LANCELOT ACS	atopaxar	placebo			Exploratory	-
J-LANCELOT, 2010	atopaxar	placebo			Exploratory	-
bivalirudin
ACUITY (biva alone vs hep+aGP2b3a), 2006 NCT	bivalirudin	heparin + GP2b3a inhibitors			Low risk of bias	suggesting
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006 NCT	bivalirudin + GP2b3a inhibitors	heparin + GP2b3a inhibitors			Low risk of bias	negative
PROTECT-TIMI 30, 2006 NCT	bivalirudin	eptifibatide + heparin			Exploratory	-
HERO, 1997	bivalirudin	heparin			Low risk of bias	suggesting
BAT (Bittl), 1995	bivalirudin	heparin			Low risk of bias	suggesting
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007	bivalirudin	heparin + GP2b3a inhibitors				suggesting
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007	bivalirudin + GP2b3a inhibitors	heparin + GP2b3a inhibitors				negative
clopidogrel
CURE (PCI sub study), 2001	clopidogrel	placebo			Low risk of bias	-
CURE, 2001	clopidogrel + aspirin	aspirin			Low risk of bias	suggesting
CURRENT OASIS 7 (clopidogrel), 2010 NCT	clopidogrel high-dose regimen	clopidogrel standard-dose			Low risk of bias	negative
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002	coumadin	control (on top of aspirin)				suggesting
ASPECT-2 (coumadin vs aspirin), 2002	coumadin	aspirin				suggesting
dalteparin
FRISC (long term), 1996	dalteparin	placebo (on top of aspirin)			Low risk of bias	suggesting
FRIC prolonged treatment phase (LWMH vs PBO), 1997	dalteparin	placebo (on top of aspirin)			Low risk of bias	negative
FRISC (short term), 1996	dalteparin	placebo (on top of aspirin)			Low risk of bias	-
FRIC (acute phase LMWH vs UFH), 1997	dalteparin	UFH (on top of aspirin)			Exploratory	negative
dipyridamol
Prandoni, 1991	aspirin + dipyridamol	placebo			Low risk of bias	negative
Efegatran
Klootwijk, 1999	Efegatran	heparin			Exploratory	-
enoxaparin
RESCUE NCT	enoxaparin	unfractionated heparin				-
EVET, 2005	enoxaparin	tinzaparin				suggesting
ESSENCE, 1997	enoxaparin	UFH (on top of aspirin)			Low risk of bias	suggesting
TIMI 11 B (short term), 1998	enoxaparin	UFH (on top of aspirin)			Low risk of bias	suggesting
SYNERGY, 2005 NCT	enoxaparin	UFH (on top of aspirin)				negative
INTERACT, 2006	enoxaparin	UFH (on top of aspirin)				suggesting
TIMI 11 B (long term), 1998	enoxaparin	UFH (on top of aspirin)			Low risk of bias	negative
fondaparinux
PENTUA, 2004	fondaparinux	enoxaparin				-
OASIS 5, 2006 NCT	fondaparinux	enoxaparin			Low risk of bias	-
hirudin
HIT-4, 1999	Hirudin	heparin			Low risk of bias	-
TIMI 9B, 1996	Hirudin	heparin			Risk of bias	-
GUSTO IIB, 1996	Hirudin	heparin			Risk of bias	-
OASIS pilot, 1997	Hirudin	heparin			Exploratory	-
HELVETICA (Serruys), 1995	Hirudin	heparin			Low risk of bias	-
OASIS 2, 1999	Hirudin	heparin			Low risk of bias	-
OASIS, 1997	Hirudin	heparin			Risk of bias	-
inogatran
TRIM, 1997	Inogatran	heparin			Low risk of bias	-
nadroparin
FRAXIS (6days), 1998	nadroparin	UFH (on top of aspirin)			Low risk of bias	negative
FRAXIS (14 days), 1998	nadroparin	UFH (on top of aspirin)			Low risk of bias	negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009 NCT	otamixaban	unfractionated heparin			Low risk of bias	suggesting
prasugrel
TRILOGY ACS (overall population), 2012 NCT	prasugrel	clopidogrel			Low risk of bias	negative
TRITON-TIMI 38, 2007 NCT	prasugrel	clopidogrel			Low risk of bias	suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011 NCT	rivaroxaban 2.5mg	placebo			Low risk of bias	suggesting
ATLAS ACS 2 - TIMI 51 (5mg), 2011 NCT	rivaroxaban 5mg	placebo				suggesting
sulfinpyrazone
Canadian (sulfinpyrazone alone), 1985	sulfinpyrazone	placebo			Low risk of bias	-
ticagrelor
PLATO, 2009 NCT	ticagrelor	clopidogrel			Low risk of bias	suggesting
DISPERSE-2 (90mg), 2007	ticagrelor	clopidogrel			Low risk of bias	negative
ticlopidine
STAI, 1990	ticlopidine	control				suggesting
Florida UA	ticlopidine	placebo				negative
trapidil
Modena	trapidil	placebo				suggesting
triflusal
TIM, 2000	triflusal	aspirin			Low risk of bias	-
Plaza, 1993	triflusal	placebo			Low risk of bias	suggesting
UFH
Holdright, 1994	UFH	control (on top of aspirin)				negative
RISC (heparin+aspirin vs ASP), 1990	UFH	control (on top of aspirin)				negative
Theroux (heparin+ASP vs ASP), 1988	UFH	control (on top of aspirin)			Low risk of bias	suggesting
ATACS (Cohen), 1994	UFH, warfarin	control (on top of aspirin)				negative
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990	UFH, warfarin	control (on top of aspirin)				negative
Theroux (heparin vs PBO), 1988	UFH	placebo			Low risk of bias	suggesting
RISC (heparin vs PBO), 1990	UFH	placebo				negative
Theroux (heparin+aspirin vs PBO), 1988	UFH + aspirin	placebo			Low risk of bias	suggesting
RISC (ASP+ heparin vs PBO), 1990	UFH + aspirin	placebo				suggesting
Gurfinkel (UFH+aspririn vs aspirin), 1995	UFH	placebo (on top of aspirin)			Low risk of bias	negative
Cohen (ATACS pilot) (heparin vs asp), 1990	UFH, warfarin	aspirin				negative
vorapaxar
TRACER, 2011 NCT	vorapaxar	placebo (on top standard therapy)			Low risk of bias	-
warfarin
ATACS (pilot study) (warfarin vs control), 1990	warfarin	control (on top of aspirin)				negative
ATACS, 1994	warfarin	control (on top of aspirin)				negative
CARS, 1997	warfarin	control (on top of aspirin)				negative
OASIS Pilot (phase 1), 1998	warfarin	control (on top of aspirin)				negative
OASIS Pilot (phase 2), 1998	warfarin	control (on top of aspirin)				negative
OASIS-2 Warfarin Substudy, 2001	warfarin	control (on top of aspirin)				negative
APRICOT-2, 2002	warfarin	control (on top of aspirin)				negative
CHAMP, 2002	warfarin	control (on top of aspirin)				negative
WARIS, 2002	warfarin	control (on top of aspirin)				suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)				negative
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)				negative
Williams, 1997	warfarin	placebo (on top of aspirin)			Low risk of bias	negative
Huyhn, 2001	warfarin	placebo (on top of aspirin)			Low risk of bias	negative
ATACS (pilot study) warfarin vs aspirin, 1990	warfarin	aspirin				negative
ximelagatran
ESTEEM, 2003	ximelagatran	placebo			Exploratory	-
acute myocardial infarction
argatroban
ARGAMI-2, 1998	Argatroban	heparin				-
bivalirudin
HERO, 1997	bivalirudin	heparin			Low risk of bias	suggesting
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin	control (on top of aspirin)				negative
ASPECT, 1994	coumadin	placebo			Low risk of bias	suggesting
ASPECT-2 (coumadin alone), 2002	coumadin	aspirin				suggesting
dalteparin
FRAMI, 1997	Dalteparin	placebo				-
BIOMACS II, 1999	Dalteparin	placebo			Low risk of bias	-
ASSENT Plus, 2003	Dalteparin	UFH				negative
enoxaparin
AMI-SK, 2002	Enoxaparin	placebo			Low risk of bias	-
ASSENT 3, 2001	Enoxaparin	UFH				suggesting
HART II, 2001	Enoxaparin	UFH				negative
Baird, 2002	Enoxaparin	UFH				negative
ENTIRE-TIMI 2, 2002	Enoxaparin	UFH				suggesting
ASSENT 3 Plus, 2003	Enoxaparin	UFH				negative
fondaparinux
MICHELANGELO OASIS-6, 2006 NCT	fondaparinux	placebo			Low risk of bias	suggesting
hirudin
HIT-4, 1999	Hirudin	heparin			Low risk of bias	-
TIMI 9B, 1996	Hirudin	heparin			Risk of bias	-
reviparin
CREATE, 2005	Reviparin	placebo			Low risk of bias	-
UFH
ISIS-2 Pilot, 1987	UFH	no heparin				negative
DUCCS, 1994	UFH	no heparin				negative
ECSG, 1992	UFH	placebo			Low risk of bias	negative
OSIRIS, 1992	UFH	placebo			Low risk of bias	negative
warfarin
APRICOT-2, 2002	warfarin	control (on top of aspirin)				suggesting
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)				negative
WARIS, 1999	warfarin	control (on top of aspirin)			Low risk of bias	-
CHAMP, 2002	warfarin	control (on top of aspirin)				negative
CARS (warafrin 3mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)			Risk of bias	suggesting
CARS (warfarin 1mg), 1997	warfarin	control (on top of aspirin)			Low risk of bias	negative
WARIS II (warfarin+ASA), 2002	warfarin	control (on top of aspirin)				suggesting
Williams, 1997	warfarin	placebo (on top of aspirin)			Low risk of bias	suggesting
WARIS II (warfarin alone), 2002	warfarin	aspirin				suggesting
atrial fibrillation
apixaban
AVERROES, 2011 NCT	apixaban	aspirin	ineligible for VKA		Low risk of bias	suggesting
ARISTOTLE, 2011 NCT	apixaban	warfarin standard dose			Low risk of bias	conclusive
phase 2 apixaban NCT	apixaban	warfarin standard dose			Exploratory	-
aspirin
LASAF(aspirin vs no treatment), 1999	aspirin	control				-
AFASAK (aspirin vs placebo), 1989	aspirin	placebo			Low risk of bias	negative
SPAF (aspirin,warfarin ineligible arm), 1991	aspirin	placebo	ineligible for VKA		Low risk of bias	negative
SPAF (aspirin , warfarin eligible arm), 1991	aspirin	placebo			Low risk of bias	suggesting
EAFT, 1993	aspirin	placebo			Low risk of bias	negative
FFAACS , 2001	aspirin	placebo (on top fluidione)			Low risk of bias	negative
PATAF (vs coumadin low dose), 1999	aspirin	coumadin low dose			Risk of bias	negative
PATAF (vs coumadin standard dose), 1999	aspirin	coumadin standard dose			Risk of bias	negative
AFASAK II (aspirin vs warfarin low dose), 1998	aspirin	warfarin low dose			Risk of bias	negative
SPAF II (aspirin vs warfarin standard dose, age<75), 1994	aspirin	warfarin standard dose			Risk of bias	negative
AFASAK II (aspirin vs warfarin standard dose), 1998	aspirin	warfarin standard dose			Risk of bias	negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994	aspirin	warfarin standard dose			Risk of bias	negative
AFASAK (aspirin vs warfarin standard dose), 1989	aspirin	warfarin standard dose			Risk of bias	negative
clopidogrel
ACTIVE W, 2006 NCT	aspirin + clopidogrel	anticoagulant			Risk of bias	suggesting
ACTIVE A, 2009 NCT	aspirin + clopidogrel	aspirin			Low risk of bias	suggesting
coumadin
PATAF (coumadin low dose vs coumadin standard dose), 1999	coumadin low dose	coumadin standard dose			Risk of bias	negative
dabigatran
RE-LY 110mg (2nd prevention subgroup) , 2010	dabigatran 100mg	warfarin			Exploratory	suggesting
RE-LY 150mg (2nd prevention subgroup)	dabigatran 150mg	warfarin			Exploratory	suggesting
phase 2 dabigatran NCT	dabigatran	warfarin standard dose			Exploratory	-
RE-LY (110mg), 2009 NCT	dabigatran 110mg	warfarin standard dose			Risk of bias	suggesting
PETRO (150mg), 2007	dabigatran 150mg	warfarin standard dose			Exploratory	-
RE-LY (150mg), 2009 NCT	dabigatran 150mg	warfarin standard dose			Risk of bias	suggesting
edoxaban
Weitz (edoxaban phase 2) NCT	edoxaban	warfarin standard dose			Exploratory	-
phase 2 edoxaban NCT	edoxaban	warfarin standard dose			Exploratory	-
ENGAGE-AF TIMI 48 High dose, 2013 NCT	edoxaban high dose	warfarin standard dose			Low risk of bias	suggesting
idraparinux
AMADEUS, 2008 NCT	idraparinux	warfarin standard dose			Risk of bias	negative
rivaroxaban
ROCKET (2nd prevention subgroup) , 2011	rivaroxaban	warfarin			Low risk of bias	negative
ROCKET-AF, 2010 NCT	rivaroxaban	warfarin standard dose			Low risk of bias	suggesting
triflusal
NASPEAF (triflusal vs coumadin standard dose)), 2004	triflusal	coumadin standard dose			Risk of bias	negative
warfarin
BAATAF (warfarin vs no treatment), 1990 NCT	warfarin low dose	control			Risk of bias	suggesting
SAFT(warfarin low dose + aspirin vs no treatment), 2003	warfarin low dose + aspirin	control			Risk of bias	negative
AFASAK (warfarin standard dose vs control), 1989	warfarin standard dose	control			Risk of bias	suggesting
SPAF (warfarin standard dose), 1991	warfarin standard dose	control			Risk of bias	suggesting
SPINAF (warfarin vs placebo), 1992	warfarin low dose	placebo			Low risk of bias	negative
CAFA, 1991	warfarin standard dose	placebo			Low risk of bias	negative
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998	warfarin + aspirin	warfarin standard dose			Risk of bias	negative
SPAF III, 1996	warfarin + aspirin	warfarin standard dose			Risk of bias	remark
AFASAK II (warfarin low dose vs warfarin standard dose), 1998	warfarin low dose	warfarin standard dose			Risk of bias	negative
MWNAF, 1998	warfarin low dose	warfarin standard dose			Risk of bias	negative
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002	ximelagatran	warfarin standard dose			Risk of bias	-
SPORTIF III, 2003	ximelagatran	warfarin standard dose			Risk of bias	suggesting
SPORTIF V, 2005	ximelagatran	warfarin standard dose			Low risk of bias	suggesting
heart failure
aspirin
WASH (aspirin), 2004	aspirin	no treatment				negative
Barzizza (ASA), 1993	aspirin	placebo			Exploratory	-
enoxaparin
THE-PRINCE (Kleber), 2003	enoxaparin	UFH				-
rivaroxaban
COMMANDER HF, 2018 NCT	rivaroxaban	placebo				negative
warfarin
WASH (warfarin), 2004	warfarin	no treatment				negative
HELAS (warfarin vs placebo), 2006	warfarin	placebo			Low risk of bias	-
Barzizza (warfarin), 1993	warfarin	placebo				-
HELAS (warfarin vs aspirin), 2006	warfarin	aspirin			Low risk of bias	-
WATCH (warfarin vs aspirin), 2009 NCT	warfarin	aspirin				suggesting
percutaneous coronary intervention
abciximab
RAPPORT, 1998	Abciximab	placebo				-
ADMIRAL, 2001	Abciximab	placebo				-
CADILLAC, 2002	Abciximab	placebo				-
EPIC (with infusion), 1994	Abciximab	placebo				-
EPILOG, 1997	Abciximab	placebo				-
EPISTENT, 1998	Abciximab	placebo				-
CAPTURE, 1997	Abciximab	placebo				-
ERASER, 1999	Abciximab	placebo				-
Petronio, 2002	Abciximab	placebo				-
Simoons, 1994	Abciximab	placebo				-
Kini, 2001	Abciximab	placebo				-
Tamburino, 2002	Abciximab	placebo				-
ISAR-2, 2000	Abciximab	placebo				-
aspirin
Taylor (Perth), 1991	aspirin	placebo			Low risk of bias	negative
M-HEART II (aspirin), 1995	aspirin	placebo			Low risk of bias	negative
bivalirudin
REPLACE-2, 2003	bivalirudin	heparin + GP2b3a inhibitors			Low risk of bias	-
HORIZONS-AMI (Stone), 2008 NCT	bivalirudin	heparin + GP2b3a inhibitors			Risk of bias	suggesting
ACUITY (Stone) (bivalirudin alone), 2006 NCT	bivalirudin	heparin + GP2b3a inhibitors			Risk of bias	-
Kleiman, 2002	bivalirudin + eptifibatide	heparin + GP2b3a inhibitors			Exploratory	-
ISAR-REACT 3, 2008 NCT	bivalirudin	UFH			Low risk of bias	-
REPLACE-1, 2004	bivalirudin	UFH			Exploratory	negative
BAT (Bittl), 1995	bivalirudin	UFH			Low risk of bias	suggesting
ARMYDA BIVALVE	bivalirudin	UFH				-
NAPLES (Tavano), 2009	bivalirudin	UFH plus tirofiban			Risk of bias	suggesting
cangrelor
CHAMPION PHOENIX, 2013 NCT	cangrelor	clopidogrel			Low risk of bias	suggesting
CHAMPION-PCI, 2009 NCT	cangrelor up front	clopidogrel up front			Low risk of bias	negative
CHAMPION-PLATFORM, 2009 NCT	cangrelor up front	delayed clopidogrel			Low risk of bias	negative
cilostazol
Kunishima, 1997	cilostazol	aspirin				negative
Sekiya, 1998	cilostazol + aspirin	aspirin				negative
Kozuma, 2001	cilostazol + aspirin	ticlopidine + aspirin				negative
Ochiai, 1999	cilostazol + aspirin	ticlopidine + aspirin				negative
Park, 1999	cilostazol + aspirin	ticlopidine + aspirin				negative
Yoon, 1999	cilostazol + aspirin	ticlopidine + aspirin				negative
Kamishirado, 2002	cilostazol + aspirin	ticlopidine + aspirin				negative
clopidogrel
GRAVITAS, 2011 NCT	high-dose clopidogrel	normal-dose clopidogrel			Risk of bias	negative
Müller, 2000	clopidogrel + aspirin	ticlopidine + aspirin				negative
CLASSICS, 2000	clopidogrel + aspirin	ticlopidine + aspirin				negative
TOPPS, 2001	clopidogrel + aspirin	ticlopidine + aspirin				negative
Piamsomboon, 2001	clopidogrel + aspirin	ticlopidine + aspirin				negative
dalteparin
Natarajan (without antiGp2b3a), 2003	dalteparin	UFH				-
Natarajan (+ antiGp2b3a), 2003	dalteparin	UFH + anti Gp2b3a				-
dipyridamol
Schwartz (Toronto), 1988	aspirin + dipyridamol	placebo			Low risk of bias	suggesting
White (aspirin+dipiridamol), 1991	aspirin + dipyridamol	placebo				negative
Nye (Dunedin), 1990	aspirin + dipyridamol	placebo				negative
Mayo-PTCA, 1989	aspirin + dipyridamol	placebo				negative
elinogrel
INNOVATE PCI NCT	elinogrel	clopidogrel				-
enoxaparin
STEEPLE, 2006 NCT	enoxaparin	UFH			Risk of bias	-
Rabah, 1999	enoxaparin	UFH			Exploratory	negative
CRUISE, 2003	enoxaparin	UFH			Exploratory	negative
Galeote, 2001	enoxaparin	UFH				negative
Dudek, 2000	enoxaparin	UFH				negative
Dudek b (enox alone), 2000	enoxaparin	UFH				-
Drozd, 2001	enoxaparin	UFH				negative
ATOLL, 2010	enoxaparin	UFH			Risk of bias	-
Dubek b (+abciximal), 2001	enoxaparin+abciximab	UFH				-
eptifibatide
IMPACT (4h), 1995	Eptifibatide	placebo				-
IMPACT-II (0.5µg), 1997	Eptifibatide	placebo				-
ESPRIT, 2000	Eptifibatide	placebo				-
Harrington, 1995	Eptifibatide	placebo				-
prasugrel
TRITOM TIMI 38 (PCI subgroup), 2009	prasugrel	clopidogrel				-
JUMBO-TIMI 26, 2005	prasugrel	clopidogrel			Low risk of bias	negative
reviparin
REDUCE, 1996	reviparin	UFH			Low risk of bias	suggesting
sulotroban
M-HEART II (sulotroban), 1995	sulotroban	placebo			Low risk of bias	-
ticlopidine
TACT, 1990	ticlopidine	placebo				negative
White (ticlopidine), 1991	ticlopidine	placebo				-
STARS (vs aspirin), 1998	ticlopidine + aspirin	aspirin				suggesting
Hall, 1996	ticlopidine + aspirin	aspirin				negative
FANTASTIC, 1998	ticlopidine + aspirin	coumadin + aspirin				negative
ISAR, 1996	ticlopidine + aspirin	coumadin + aspirin				suggesting
Foussas, 2000	ticlopidine + aspirin	coumadin + aspirin				suggesting
MATTIS, 1998	ticlopidine + aspirin	coumadin + aspirin				negative
STARS (vs coumadin+asp), 1998	ticlopidine + aspirin	coumadin + aspirin				suggesting
tirofiban
RESTORE, 1997	Tirofiban	placebo				-
Kereiakis, 1996	Tirofiban	placebo				-
peripheral vascular diseases
acenocoumarol
APIC, 1989	acenocoumarol	placebo				-
aspirin
Lassila R, 1991	aspirin	contrôle				-
CLIPS, 2007	aspirin	placebo			Low risk of bias	suggesting
BOA, 2000	aspirin					-
ticlopidine
Becquemin, 1997	ticlopidine	contrôle				-
UFH
Antonicelli, 1999	HNF	placebo				-
Tesi, 1989	HNF	placebo				-
warfarin
Johnson, 2002	warfarin	contrôle				-
Sarac, 1998	warfarin	contrôle				-
post acute coronary syndromes
dabigatran
REDEEM, 2009 NCT	dabigatran	placebo			Low risk of bias	negative
post myocardial infarction
dabigatran
REDEEM, 2009 NCT	dabigatran	placebo			Low risk of bias	negative
pulmonary embolism
apixaban
AMPLIFY-EXT 2.5mg, 2012 NCT	apixaban 2.5mg	discontinuation			Low risk of bias	suggesting
AMPLIFY-EXT 5mg, 2012 NCT	apixaban 5mg	discontinuation			Low risk of bias	suggesting
AMPLIFY, 2013 NCT	apixaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
Certoparin
Certoparin-Study Group sub group, 1998	Certoparin	unfractionated heparin			Exploratory	negative
dalteparin
Kuijer, 1995	Dalteparin	unfractionated heparin				negative
Meyer, 1995	Dalteparin	unfractionated heparin				negative
enoxaparin
PREPIC, 1998	Enoxaparin	unfractionated heparin			Risk of bias	negative
Merli sub group, 2001	Enoxaparin	unfractionated heparin			Exploratory	negative
fondaparinux
MATISSE PE, 2003	fondaparinux	heparin			Risk of bias	negative
idraparinux
VanGogh PE, 2007 NCT	idraparinux (without heparin)	heparin/VKA			Risk of bias	negative
nadroparin
European multicentre study, 1991	Nadroparin	unfractionated heparin			Risk of bias	negative
Prandoni sub-group, 1992	Nadroparin	unfractionated heparin			Exploratory	negative
Thery, 1992	Nadroparin	unfractionated heparin			Exploratory	negative
reviparin
COLOMBUS sub group, 1997	Reviparin	unfractionated heparin			Exploratory	negative
rivaroxaban
Einstein-PE Evaluation, 2012 NCT	rivaroxaban (without LMWH)	LMWH/VKA			Risk of bias	-
tinzaparin
ACTSG (Hull) sub-group, 1992	Tinzaparin	unfractionated heparin			Low risk of bias	negative
THESEE, 1997	Tinzaparin	unfractionated heparin			Risk of bias	negative
Campbell, 1998	Tinzaparin	unfractionated heparin				negative
stable angina
aspirin
SAPAT, 1992	aspirin	placebo			Low risk of bias	suggesting
clopidogrel
ASCET NCT	clopidogrel	aspirin			Risk of bias	negative
dipyridamol
Atlanta (Sbar), 1967	dipyridamol	control			Low risk of bias	negative
Becker, 1967	dipyridamol	control			Low risk of bias	negative
Wirecki, 1967	dipyridamol	control			Low risk of bias	negative
Igloe, 1970	dipyridamol	placebo			Low risk of bias	-
Zion, 1961	dipyridamol	placebo			Low risk of bias	-
Kinsella, 1962	dipyridamol	placebo			Low risk of bias	-
Leiberman, 1964	dipyridamol	placebo			Low risk of bias	-
Dewar, 1961	dipyridamol	placebo			Low risk of bias	-
Neumann, 1964	dipyridamol	placebo			Low risk of bias	-
Foulds, 1960	dipyridamol	placebo			Low risk of bias	-
ticlopidine
Berglund, 1985	ticlopidine	placebo			Low risk of bias	negative
stent
cilostazol
Kunishima, 1997	cilostazol	aspirin				negative
Sekiya, 1998	cilostazol + aspirin	aspirin				negative
Kozuma, 2001	cilostazol + aspirin	ticlopidine + aspirin				negative
Ochiai, 1999	cilostazol + aspirin	ticlopidine + aspirin				negative
Park, 1999	cilostazol + aspirin	ticlopidine + aspirin				negative
Yoon, 1999	cilostazol + aspirin	ticlopidine + aspirin				negative
Kamishirado, 2002	cilostazol + aspirin	ticlopidine + aspirin				negative
clopidogrel
REAL-LATE, ZEST-LATE, 2010 NCT	clopidogrel+aspirin	aspirin				negative
GRAVITAS, 2011 NCT	high-dose clopidogrel	normal-dose clopidogrel			Risk of bias	negative
Müller, 2000	clopidogrel + aspirin	ticlopidine + aspirin				negative
CLASSICS, 2000	clopidogrel + aspirin	ticlopidine + aspirin				negative
TOPPS, 2001	clopidogrel + aspirin	ticlopidine + aspirin				negative
Piamsomboon, 2001	clopidogrel + aspirin	ticlopidine + aspirin				negative
ticlopidine
STARS (vs aspirin), 1998	ticlopidine + aspirin	aspirin				suggesting
Hall, 1996	ticlopidine + aspirin	aspirin				negative
FANTASTIC, 1998	ticlopidine + aspirin	coumadin + aspirin				negative
ISAR, 1996	ticlopidine + aspirin	coumadin + aspirin				suggesting
Foussas, 2000	ticlopidine + aspirin	coumadin + aspirin				suggesting
MATTIS, 1998	ticlopidine + aspirin	coumadin + aspirin				negative
STARS (vs coumadin+asp), 1998	ticlopidine + aspirin	coumadin + aspirin				suggesting
superficial thrombophlebitis
candesartan
Andreozzi (200 vs 100), 1996	desmin 200	desmin 100				-
Andreozzi (desmin SC vs 100), 1996	desmin SC	desmin 100				-
coumadin
Belcaro (coumadin vs low dose hep), 1999	coumadin	low dose heparin				-
defibrotide
Belcaro, 1990	defibrotide	low dose heparin				-
Diclofenac
Nocker (diclofenac), 1991	Diclofenac	placebo				-
enoxaparin
Stenox (enoxaparin 40mg), 2003	enoxaparin	placebo				-
STENOX (enoxaparin 1.5mg/hg), 2003	enoxaparin	placebo				-
fondaparinux
CALISTO, 2010 NCT	fondaparinux	placebo			Low risk of bias	suggesting
heparin
Belcaro (hep vs defibrotide), 1990	heparin					-
Gorski, 2005	heparin spraygel	clexane				-
Katzenschlager, 2003	liposomal heparin-spraygel	enoxaparin				-
Marchiori, 2002	heparin	low dose UFH				-
Belcaro (hep vs no hep), 1989	heparin	no treatment				-
nadroparin
Vesalio, 2005	nadroparin fixed-dose	nadroparin weight-adjusted				-
Titon (nadroparin 0.6ml vs naproxen), 1994	nadroparin	naproxene				-
Titon (nadroparin 61.5 IU anti-Xa/kg vs naproxen), 1994	nadroparin	naproxene				-
Nimesulide
Ferrari, 1992	Nimesulide	diclofenac				-
UFH
Belcaro (prophylactic UFH vs no), 1999	Prophylactic UFH	no treatment				-
thrombosis prevention
acenocoumarol
Hamulyak, 1994	Acenocoumarol	Nadroparin				negative
Samama, 2001	Acenocoumarol	Reviparin				negative
van Geloven, 1977	Acenocoumarol	unfractionated heparin			Low risk of bias	-
apixaban
ADOPT, 2011 NCT	apixaban	enoxaparin	medical patients		Low risk of bias	suggesting
ADVANCE 3, 2010 NCT	apixaban	enoxaparin	hip surgery		Low risk of bias	suggesting
ADVANCE 2, 2010 NCT	apixaban	enoxaparin (europe regimen)	knee surgery		Low risk of bias	suggesting
APROPOS 2.5mg, 2007 NCT	apixaban	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
ardeparin
Levine, 1996	ardeparin	placebo	knee surgery		Low risk of bias	suggesting
Heit, 2000	out of hospital Ardeparin	standard prophylaxis				negative
Godwin, 1993	ardeparin	unfractionated heparin	abdominal surgery			-
aspirin
Clagett, 1975	aspirin	control			Risk of bias	-
Zekert VI, 1982	aspirin	control			Risk of bias	-
Pasteyer, 1977	Aspirin	no treatment			Exploratory	negative
Rocha, 1986	Aspirin	no treatment			Exploratory	suggesting
PEP hip-fracture, 2000	aspirin	placebo			Low risk of bias	suggesting
Stockholm-I, 1975	Aspirin	placebo			Exploratory	negative
Harris-I, 1977	Aspirin	placebo			Low risk of bias	suggesting
McKenna-I, 1980	Aspirin	placebo			Exploratory	suggesting
Sautter, 1983	Aspirin	placebo			Exploratory	suggesting
McBride, 1983	Aspirin	placebo			Exploratory	negative
Zekert-I , 1974	Aspirin	placebo			Exploratory	suggesting
Powers , 1976	Aspirin	placebo			Exploratory	suggesting
Erfurt-B , 1979	Aspirin	placebo			Exploratory	negative
MRC, 1972	aspirin	placebo			Low risk of bias	negative
Loew DVT, 1974	aspirin	placebo			Low risk of bias	-
Erfurt-A, 1979	aspirin	placebo			Low risk of bias	-
Zekert V, 1980	aspirin	placebo			Low risk of bias	-
Vinazzer I, 1980	aspirin	placebo			Low risk of bias	-
Vinazzer II, 1977	aspirin	placebo			Low risk of bias	-
PEP elective arthroplasty, 2000	aspirin	placebo			Low risk of bias	-
betrixaban
APEX, 2016 NCT	betrixaban	enoxaparin	medical patients		Low risk of bias	suggesting
candesartan
Ericksson, 1997	desirudin	enoxaparin			Low risk of bias	-
REVASC, 1997	desirudin	UFH				-
Eriksson, 1996	desirudin	UFH			Low risk of bias	-
Certoparin
Kock, 1995	certoparin	control			Risk of bias	negative
CERTIFY, 2010	certoparin	UFH	medical patients			-
Schmitz-Huebner, 1984	certoparin	unfractionated heparin	abdominal surgery			negative
Sasahara, 1986	certoparin	unfractionated heparin	abdominal surgery			suggesting
Voigt, 1986	certoparin	unfractionated heparin	abdominal surgery			negative
Welzel, 1988	certoparin	unfractionated heparin	abdominal surgery			suggesting
Kakkar, 1989	certoparin	unfractionated heparin	abdominal surgery			negative
Adolf, 1989	certoparin	unfractionated heparin	abdominal surgery			negative
Heilmann, 1989	certoparin	unfractionated heparin	gynaecological surgery			negative
Baumgartner, 1989	certoparin	unfractionated heparin	abdominal surgery			negative
Hoffmann and Largiade, 1990	certoparin	unfractionated heparin	abdominal surgery			negative
Koppenhagen, 1990	certoparin	unfractionated heparin	abdominal surgery			-
Schielke, 1991	certoparin	unfractionated heparin	abdominal surgery			-
Koppenhagen, 1992	certoparin	unfractionated heparin	abdominal surgery			-
Hoffmann and Largiader, 1992	certoparin	unfractionated heparin	abdominal surgery			-
Heilmann, 1997	certoparin	unfractionated heparin	gynaecological surgery			-
Haas, 1999	certoparin	unfractionated heparin	general surgery			-
Haas , 1987	certoparine + DHE	Unfractionated heparin	hip surgery			negative
Lassen, 1988	certoparine + DHE	Unfractionated heparin	hip surgery		Low risk of bias	suggesting
Lassen, 1989	certoparine + DHE	Unfractionated heparin	hip surgery		Low risk of bias	negative
dabigatran
RE-NOVATE (150mg), 2007 NCT	dabigatran 150mg	enoxaparin	hip surgery		Low risk of bias	negative
RE-NOVATE (220mg), 2007 NCT	dabigatran 220mg	enoxaparin	hip surgery		Low risk of bias	negative
RE-NOVATE 2 NCT	dabigatran 220mg	enoxaparin	hip surgery		Low risk of bias	negative
RE-MODEL (150mg), 2007	dabigatran 150mg	enoxaparin (europe regimen)	knee surgery		Low risk of bias	negative
RE-MODEL (220mg), 2007	dabigatran 220mg	enoxaparin (europe regimen)	knee surgery		Low risk of bias	negative
RE-MOBILIZE (150mg), 2008	dabigatran 150mg	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
RE-MOBILIZE (220mg), 2008	dabigatran 220mg	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
dalteparin
Jorgensen, 1989	dalteparin	placebo	hip surgery		Low risk of bias	suggesting
Torholm, 1991	dalteparin	placebo	hip surgery		Low risk of bias	suggesting
Leizorovicz, 2004	dalteparin	placebo	medical patients		Low risk of bias	suggesting
Ockelford , 1989	dalteparin	placebo				suggesting
Lapidus, 2007	dalteparin	placebo			Low risk of bias	negative
Lapidus, 2007	dalteparin	placebo			Low risk of bias	negative
D-KAf (Selby), 2007 NCT	dalteparin	placebo				negative
Eriksson , 1988	dalteparin	Dextran	hip surgery			suggesting
Matzsch , 1988	dalteparin	Dextran	hip surgery			negative
Matzsch , 1991	dalteparin	Dextran	hip surgery			suggesting
Dahl, 1997	out of hospital Dalteparin	standard prophylaxis				suggesting
Lassen, 1998	out of hospital Dalteparin	standard prophylaxis				negative
Hull, 2000	out of hospital Dalteparin	standard prophylaxis				suggesting
PROTECT, 2011 NCT	dalteparin	UFH	medical patients		Low risk of bias	suggesting
Scala, 1990	dalteparin	UFH			Risk of bias	negative
Haas , 1985	dalteparin	Unfractionated heparin	hip surgery			negative
Binsack , 1986	dalteparin	Unfractionated heparin	hip surgery			negative
Barre , 1987	dalteparin	Unfractionated heparin	hip surgery			negative
Dechavanne , 1989	dalteparin	Unfractionated heparin	hip surgery			negative
Eriksson , 1989	dalteparin	Unfractionated heparin	hip surgery			suggesting
Monreal , 1989	dalteparin	Unfractionated heparin	hip surgery			negative
Bergqvist, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Onarheim, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Koller, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Koller, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Fricker, 1988	dalteparin	unfractionated heparin	abdominal surgery			negative
Bergqvist, 1988	dalteparin	unfractionated heparin	abdominal surgery			negative
Caen, 1988	dalteparin	unfractionated heparin	abdominal surgery			negative
Borstad, 1988	dalteparin	unfractionated heparin	gynaecological surgery			negative
Briel, 1988	dalteparin	unfractionated heparin	non orthopedic surgery			negative
Creperio, 1990	dalteparin	unfractionated heparin	general surgery			negative
Hartl, 1990	dalteparin	unfractionated heparin	abdominal surgery			suggesting
Borstad, 1992	dalteparin	unfractionated heparin	gynaecological surgery			-
Kakkar, 1993	dalteparin	unfractionated heparin	abdominal surgery			-
deltaparin
Michot, 2002	deltaparin	control			Risk of bias	suggesting
dipyridamol
Chicago, 1982	aspirin + dipyridamol	control			Exploratory	negative
Parodi I, 1973	dipyridamol + aspirin	control			Exploratory	suggesting
Parodi II, 1973	dipyridamol + aspirin	control			Risk of bias	-
Zekert-III, 1977	dipyridamol + aspirin	control			Risk of bias	-
Australian I, 1975	dipyridamol + aspirin	control			Risk of bias	-
Australian II, 1976	dipyridamol + aspirin	control			Risk of bias	-
Toulouse I, 1979	dipyridamol + aspirin	control			Risk of bias	-
Harjola DVT, 1982	dipyridamol + aspirin	control			Risk of bias	-
Weiss, 1977	dipyridamol + aspirin	control			Exploratory	-
Lyon-I, 1975	aspirin + dipyridamol	no treatment			Exploratory	suggesting
Morris-B , 1977	aspirin + dipyridamol	no treatment			Exploratory	negative
Morris-A , 1977	dipyridamol	no treatment			Exploratory	negative
Hamburg, 1976	aspirin + dipyridamol	placebo			Exploratory	negative
Encke-II , 1976	aspirin + dipyridamol	placebo			Exploratory	negative
Frankfurt, 1981	aspirin + dipyridamol	placebo			Low risk of bias	negative
Encke IA, 1976	dipyridamol + aspirin	placebo			Low risk of bias	-
Encke IB, 1976	dipyridamol + aspirin	placebo			Low risk of bias	-
edoxaban
STARS J-V NCT	edoxaban	enoxaparin (short duration)	hip surgery		Low risk of bias	suggesting
enoxaparin
Canata, 2003	enoxaparin	control			Exploratory	negative
Warwick, 1995	enoxaparin	no treatment	hip surgery			negative
Ho [43]	enoxaparin	no treatment				negative
Turpie, 1986	enoxaparin	placebo	hip surgery		Low risk of bias	suggesting
Leclerc, 1991	enoxaparin	placebo	knee surgery		Low risk of bias	suggesting
Samama, 1997	enoxaparin	placebo	hip surgery		Low risk of bias	suggesting
Kalodiki, 1996	enoxaparin	placebo	hip surgery		Low risk of bias	-
MEDENOX, 1999	Enoxaparin	placebo	medical patients		Low risk of bias	suggesting
Lederle, 2006	Enoxaparin	placebo	medical patients		Low risk of bias	negative
LIFENOX, 2011 NCT	enoxaparin	placebo	medical patients		Low risk of bias	negative
LeGagneux , 1987	enoxaparin	placebo				negative
Agnelli, 1998	enoxaparin	placebo				suggesting
Melon, 1987	enoxaparin	placebo				negative
DES Group , 1991	enoxaparin	Dextran	hip surgery			suggesting
Bergqvist, 1996	out of hospital Enoxaparin	standard prophylaxis				suggesting
Planes, 1996	out of hospital Enoxaparin	standard prophylaxis				negative
Comp, 2001	out of hospital Enoxaparin	standard prophylaxis				suggesting
Bergmann and Neuhart, 1996	enoxaparin	UFH	medical patients		Low risk of bias	negative
Lechler, 1996	enoxaparin	UFH	medical patients		Low risk of bias	negative
Kleber, 2003	enoxaparin	UFH	medical patients			negative
Planes , 1988	enoxaparin	Unfractionated heparin	hip surgery			suggesting
Levine , 1991	enoxaparin	Unfractionated heparin	hip surgery			negative
Samama 1, 1988	enoxaparin	unfractionated heparin	general surgery			negative
Samama 2, 1988	enoxaparin	unfractionated heparin	general surgery			negative
Samama 3, 1988	enoxaparin	unfractionated heparin	general surgery			negative
Kaaja, 1992	enoxaparin	unfractionated heparin	gynaecological surgery			-
Gazzaniga (ISG), 1993	enoxaparin	unfractionated heparin	general surgery			-
Nurmohamed, 1995	enoxaparin	unfractionated heparin	general surgery			-
McLeod (Canadian), 1995	enoxaparin	unfractionated heparin	abdominal surgery			-
Gonzalez, 1996	enoxaparin	unfractionated heparin	abdominal surgery			-
ENOXACAN, 1997	enoxaparin	unfractionated heparin	abdominal surgery			-
fondaparinux
DRI4757	fondaparinux	placebo	knee surgery		Low risk of bias	-
ARTEMIS (Cohen), 2006	fondaparinux	placebo	medical patients		Low risk of bias	negative
APOLLO (Turpie), 2007	fondaparinux	placebo (on top intermittent pneumatic comp.)	abdominal surgery		Low risk of bias	suggesting
PENTAMAKS (Bauer), 2001	fondaparinux	enoxaparin	knee surgery		Low risk of bias	suggesting
PENTHIFRA (Eriksson), 2001	fondaparinux	enoxaparin	hip surgery		Low risk of bias	suggesting
PENTATHLON (Turpie), 2002	fondaparinux	enoxaparin	hip surgery		Low risk of bias	suggesting
EPHESUS (Lassen), 2002	fondaparinux	enoxaparin	hip surgery		Low risk of bias	suggesting
Turpie, 2001	fondaparinux	enoxaparin	hip surgery		Low risk of bias	-
L8541	fondaparinux	enoxaparin	orthopaedic surgery		Low risk of bias	negative
L8635	fondaparinux	enoxaparin	knee surgery		Exploratory	negative
BRiEF NCT	fondaparinux	enoxaparin	medical patients			-
PEGASUS, 2005	fondaparinux	enoxaparin	abdominal surgery		Low risk of bias	negative
fraxiparin
Roth, 1995	nadroparin	control				negative
Pezzuoli, 1989	nadroparin	placebo				suggesting
Leyvraz, 1991	nadroparin	Unfractionated heparin	hip surgery			negative
LMWH
Harenberg, 1990	LMWH	UFH	medical patients		Low risk of bias	negative
Harenberg, 1996	LMWH	UFH	medical patients		Low risk of bias	negative
nadroparin
KANT (7 days), 2008	nadroparin	control			Risk of bias	suggesting
Kujath, 1993	nadroparin	control			Risk of bias	suggesting
KANT (14 days), 2008	nadroparin 14d	control			Risk of bias	suggesting
Yoo, 1997	nadroparin	no treatment	hip surgery			negative
Marassi [41]	nadroparin	no treatment				negative
Sourmelis, 1995	nadroparin	placebo	hip surgery		Low risk of bias	suggesting
Fraisse, 2000	Nadroparin	placebo	medical patients		Low risk of bias	negative
Mahe, 2005	Nadroparin	placebo	medical patients		Low risk of bias	negative
Bergmann, 1996	nadroparin	placebo	medical patients			negative
Balas [40]	nadroparin	placebo				negative
Nurmohamed, 1996	nadroparin	placebo				negative
NPHDO, 1998	out of hospital Nadroparin	standard prophylaxis				negative
Kakkar and Murray, 1985	nadroparin	unfractionated heparin	general surgery			suggesting
EFS, 1988	nadroparin	unfractionated heparin	abdominal surgery			suggesting
Dahan, 1989	nadroparin	unfractionated heparin	thoracic surgery			negative
Barbui, 1990	nadroparin	unfractionated heparin	general surgery			-
Eurin, 1994	nadroparin	unfractionated heparin	abdominal surgery			-
phenindione
Eskeland, 1966	Phenindione	no treatment				-
Hamilton, 1970	Phenindione	no treatment				-
reviparin
Wirth, 2001	reviparin	control			Low risk of bias	negative
Lassen, 2002	reviparin	placebo			Low risk of bias	suggesting
Kakkar, 1993	reviparin	unfractionated heparin	general surgery			-
rivaroxaban
MARINER, 2018 NCT	rivaroxaban	placebo	medical patients		Low risk of bias	suggesting
RECORD 1, 2008 NCT	rivaroxaban	enoxaparin	hip surgery		Low risk of bias	suggesting
RECORD 3, 2008 NCT	rivaroxaban	enoxaparin (europe regimen)	knee surgery		Low risk of bias	suggesting
ODIXa-HIP 10mg, 2006	rivaroxaban	enoxaparin (short duration)	hip surgery		Low risk of bias	suggesting
RECORD 2, 2008 NCT	rivaroxaban (long duration)	enoxaparin (short duration)	hip surgery		Low risk of bias	suggesting
ODIXa-KNEE, 2005	rivaroxaban	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
RECORD 4, 2009 NCT	rivaroxaban	enoxaparin (US regimen)	knee surgery		Low risk of bias	suggesting
suloctidil
Turpie, 1985	Suloctidil	placebo			Low risk of bias	-
ticlopidine
McKenna-II, 1983	Ticlopidine	placebo			Exploratory	negative
Lyon-II	Ticlopidine	placebo			Exploratory	negative
Gardecki	Ticlopidine	placebo			Exploratory	negative
McKenna-II , 1983	ticlopidine	placebo			Low risk of bias	negative
Lasierra, 1982	ticlopidine	placebo			Low risk of bias	-
Walker, 1974	ticlopidine	placebo			Low risk of bias	-
tinzaparin
Jorgensen, 2002	tinzaparin	control			Risk of bias	negative
Lassen, 1991	tinzaparin	placebo	hip surgery		Low risk of bias	suggesting
Bergqvist [42]	tinzaparin	placebo				negative
Leizorovicz, 1991	tinzaparin	unfractionated heparin	abdominal surgery			-
UFH
Blech, 1981	UFH	control	medical patients			suggesting
Cade	UFH	control	medical patients			-
Gardlund, 1996	UFH	control	medical patients			suggesting
Handley (low dose), 1972	UFH	control			Risk of bias	negative
Handley, 1972	UFH	control			Risk of bias	negative
Gallus, 1973	UFH	control			Risk of bias	negative
Emerson, 1973	UFH	control			Risk of bias	suggesting
Zawilska, 1989	UFH	control			Risk of bias	suggesting
Warlow, 1973	UFH	control			Low risk of bias	suggesting
Morris, 1974	UFH	no treatment				suggesting
Welin-Berger, 1982	UFH	no treatment				negative
Bergqvist , 1979	UFH	no treatment				suggesting
VTCSG, 1975	UFH	no treatment				negative
Mannucci , 1976	UFH	no treatment				suggesting
Dechavanne, 1974	UFH	no treatment				suggesting
Dechavanne, 1975	UFH	no treatment				suggesting
Bergqvist, 1979	UFH	no treatment				suggesting
Galasko , 1976	UFH	no treatment				suggesting
Gallus , 1973	UFH	no treatment				suggesting
Morris , 1977	UFH	no treatment				negative
Kakkar (IMT)	UFH	no treatment				-
Gruber	UFH	no treatment				-
Gordon-Smith, 1972	UFH	no treatment				-
Nicolaides, 1972	UFH	no treatment				-
Multiunit, 1974	UFH	no treatment				-
Abernethy, 1974	UFH	no treatment				-
Clarke-Pearson, 1983	UFH	no treatment				-
Plante, 1979	UFH	no treatment				-
Abraham-Inpijn, 1979	UFH	no treatment				-
Spebar, 1981	UFH	no treatment				-
Sagar, 1974	UFH	no treatment				-
Koppenhagen, 1982	UFH	no treatment				-
Bergqvist, 1980	UFH	no treatment				-
Gallus, 1973	UFH	no treatment				-
Gallus, 1976	UFH	no treatment				-
Groote Schuur, 1979	UFH	no treatment				-
Kraytman, 1976	UFH	no treatment				-
Kraytman, 1977	UFH	no treatment				-
Kettunen, 1974	UFH	no treatment				-
Caloghera, 1984	UFH	no treatment				-
Marchelli, 1983	UFH	no treatment				-
Ziemski, 1979	UFH	no treatment				-
Coe, 1978	UFH	no treatment				-
Sebeseri, 1975	UFH	no treatment				-
Allen, 1978	UFH	no treatment				-
Cerrato, 1978	UFH	no treatment				suggesting
Williams , 1978	UFH	placebo				negative
Abraham-Inpijn , 1975	UFH	placebo				negative
Lowe , 1981	UFH	placebo				suggesting
Hampson, 1974	UFH	placebo				negative
Moskovitz, 1978	UFH	placebo				suggesting
Lahnborg, 1980	UFH	placebo				suggesting
Xabregas , 1977	UFH	placebo				negative
Moskovitz, 1978	UFH	placebo				negative
Svend-Hansen, 1981	UFH	placebo				suggesting
Kakkar, 1972	UFH	placebo				-
Kiil, 1978	UFH	placebo				-
Torngren, 1978	UFH	placebo				-
Torngren	UFH	placebo				-
Lahnborg, 1975	UFH	placebo				-
Lahnborg, 1976	UFH	placebo				-
Covey, 1975	UFH	placebo				-
Belch, 1980	UFH	placebo				-
Taberner, 1978	UFH	placebo				-
Strand, 1975	UFH	placebo				-
Roberts, 1975	UFH	placebo				-
Ribaudo, 1975	UFH	placebo				-
Wu, 1977	UFH	placebo				-
Lawrence, 1977	UFH	placebo				-
Muiticentre, 1984	UFH	placebo				-
Jourdan, 1984	UFH	placebo				-
Torngren, 1978	UFH	placebo				-
Kruse-Blinkenberg, 1980	UFH	placebo				-
Kraytman, 1977	UFH	placebo				-
Marchetti, 1982	UFH	placebo				-
Bejjani, 1983	UFH	placebo				-
Hedlund, 1979	UFH	placebo				-
Kutnowski, 1977	UFH	placebo				-
Vandendris, 1980	UFH	placebo				-
Pitt, 1980	UFH	placebo			Risk of bias	negative
Loew, 1977	UFH	aspirin				-
Vinazzer, 1980	UFH	aspirin				-
Muiticentre 53,S4, 1984	UFH	DHE				-
Muiticentre, 1984	UFH	DHE				-
van Geloven, 1977	UFH	oral anticoagulant				-
Manganelli, 1998	out of hospital UFH	standard prophylaxis				negative
warfarin
Pinto, 1970	Warfarin	no treatment				-
Hume, 1973	Warfarin	no treatment				-
Morris, 1976	Warfarin	no treatment				-
Powers, 1989	Warfarin	no treatment				-
Myrhe, 1969	Warfarin	placebo			Low risk of bias	-
RD Heparin, 1994	Warfarin	Ardeparin				suggesting
Heit, 1997	Warfarin	Ardeparin			Low risk of bias	suggesting
Powers, 1989	Warfarin	Aspirin				-
Lotke, 1997	Warfarin	Aspirin				-
Francis, 1997	Warfarin	Dalteparin				suggesting
Hull, 2000	Warfarin	Dalteparin			Low risk of bias	suggesting
Gerhart, 1991	Warfarin	Danaparoid				-
van Comp, 1998	Warfarin	Danaparoid				-
Myrhe, 1969	Warfarin	Dextran			Low risk of bias	-
Harris, 1972	Warfarin	Dextran				-
Barber, 1977	Warfarin	Dextran				-
Francis, 1983	Warfarin	Dextran				-
Leclerc, 1996	Warfarin	Enoxaparin			Low risk of bias	suggesting
Colwell, 1999	Warfarin	Enoxaparin				suggesting
Fitzgerald, 2001	Warfarin	Enoxaparin				suggesting
Paiement, 1987	Warfarin	Intermittent pneumatic compression				-
Bailey, 1991	Warfarin	Intermittent pneumatic compression				-
Kaempffe, 1991	Warfarin	Intermittent pneumatic compression				-
Francis, 1992	Warfarin	Intermittent pneumatic compression				-
Hull, 1993	Warfarin	Logiparin			Low risk of bias	suggesting
Hume, 1973	Warfarin	Sudoxicam				-
Hume, 1973	Warfarin	unfractionated heparin				-
Barber, 1977	Warfarin	unfractionated heparin				-
ximelagatran
METHRO I, 2002	ximelagatran	Dalteparin				negative
METHRO II, 2002	ximelagatran	Dalteparin			Low risk of bias	suggesting
Phase II (Heit), 2001	ximelagatran	Enoxaparin			Low risk of bias	negative
Platinum (Colwell), 2003	ximelagatran	Enoxaparin			Low risk of bias	negative
METHRO III, 2002	ximelagatran	Enoxaparin			Low risk of bias	negative
EXPRESS, 2003	ximelagatran	Enoxaparin			Low risk of bias	suggesting
venous thrombosis
apixaban
AMPLIFY-EXT 2.5mg, 2012 NCT	apixaban 2.5mg	discontinuation			Low risk of bias	suggesting
AMPLIFY-EXT 5mg, 2012 NCT	apixaban 5mg	discontinuation			Low risk of bias	suggesting
Botticelli DVT, 2008 NCT	apixaban (without LMWH)	LMWH/VKA			Exploratory	-
AMPLIFY, 2013 NCT	apixaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
aspirin
WARFASA, 2012 NCT	aspirin	discontinuation			Low risk of bias	suggesting
ASPIRE, 2012	aspirin	discontinuation				suggesting
Bemiparin
Kakkar, 2003	Bemiparin	warfarin			Risk of bias	negative
dabigatran
RE-MEDY, 2011 NCT	dabigatran	warfarin			Low risk of bias	suggesting
RE-SONATE, 2011 NCT	dabigatran	discontinuation			Low risk of bias	suggesting
RE-COVER, 2009 NCT	heparin/dabigatran	heparin/VKA		heparin - DOAC	Low risk of bias	suggesting
dalteparin
CLOT (Lee), 2003	extended dalteparin	standard treatment				suggesting
Das, 1996	Dalteparin	warfarin			Risk of bias	negative
Lee, 2003	Dalteparin	warfarin			Risk of bias	suggesting
Holmström, 1992	once daily dalteparin	twice daily dalteparin				negative
Partsch, 1996	once daily dalteparin	twice daily dalteparin				negative
Bratt et al , 1985	Dalteparin	unfractionated heparin				negative
Holm et al , 1986	Dalteparin	unfractionated heparin				negative
Bratt et al, 1990	Dalteparin	unfractionated heparin				negative
Lindmarker et al , 1993	Dalteparin	unfractionated heparin				negative
edoxaban
Hokusai-VTE Cancer, 2017 NCT	edoxaban	dalteparin	patients with cancer		Risk of bias	negative
enoxaparin
Veiga, 2000	Enoxaparin	acenocoumarol			Risk of bias	negative
González-Fajardo, 2008	Enoxaparin	coumarin			Risk of bias	-
Cesarone, 2003	extended enoxaparin	standard treatment				negative
Deitcher, 2006	extended enoxaparin	standard treatment				negative
Meyer, 2002	extended enoxaparin	standard treatment				negative
Pini, 1994	Enoxaparin	warfarin			Risk of bias	negative
Gonzalez-Fajardo, 1999	Enoxaparin	warfarin			Risk of bias	suggesting
Meyer, 2002	Enoxaparin	warfarin			Risk of bias	negative
Deitcher, 2003	Enoxaparin	warfarin			Risk of bias	negative
Merli, 2001	once daily enoxaparin	twice daily enoxaparin			Low risk of bias	negative
Merli (once daily vs UFH), 2001	once daily enoxaparin	UFH			Low risk of bias	negative
Simonneau et al , 1993	Enoxaparin	unfractionated heparin				negative
fondaparinux
MATISSE, 2004	fondaparinux	enoxaparin			Low risk of bias	negative
MATISSE PE, 2003	fondaparinux	heparin			Risk of bias	negative
heparin
Ott importé, 1998	heparin+warfarin	placebo			Low risk of bias	negative
Krahenbuhl, 1979	subcutaneous heparin	intravenous heparin				-
Bentley, 1980	subcutaneous heparin	intravenous heparin				suggesting
Andersson, 1982	subcutaneous heparin	intravenous heparin				-
Hull, 1986	subcutaneous heparin	intravenous heparin				negative
Doyle, 1987	subcutaneous heparin	intravenous heparin				negative
Walker, 1987	subcutaneous heparin	intravenous heparin				suggesting
Lopaciuk	subcutaneous heparin	intravenous heparin				negative
Pini, 1990	subcutaneous heparin	intravenous heparin				negative
Nielsen importé, 1994	heparin+phenprocoumon	phenylbutazone				-
idraparinux
Van Gogh (subgroup), 2011	idraparinux	standard treatment	patients with cancer		Exploratory	negative
VanGogh DVT, 2007 NCT	idraparinux (without heparin)	heparin/VKA			Exploratory	suggesting
VanGogh PE, 2007 NCT	idraparinux (without heparin)	heparin/VKA			Risk of bias	negative
logiparin
Siegbahn, 1989	once daily logiparin	twice daily logiparin				negative
nadroparin
Lopaciuk, 1999	Nadroparin	acenocoumarol			Risk of bias	negative
Lopez-Beret, 2001	Nadroparin	acenocoumarol			Risk of bias	negative
Lopez Beret, 2001	extended nadroparin	standard treatment				negative
Charbonnier, 1998	once daily nadroparin	twice daily nadroparin			Low risk of bias	negative
Collaborative European Multicentre, 1991	Nadroparin	unfractionated heparin				negative
Prandoni et al , 1992	Nadroparin	unfractionated heparin				suggesting
Lopaciuk et al , 1992	Nadroparin	unfractionated heparin				negative
rivaroxaban
SELECT D, 2018	rivaroxaban	dalteparin	patients with cancer		Risk of bias	suggesting
EINSTEIN-extension, 2009 NCT	rivaroxaban	discontinuation			Low risk of bias	suggesting
EINSTEIN (subgroup), 2014	rivaroxaban	enoxaparin	patients with cancer			suggesting
Einstein-DVT Dose-Ranging Study, 2008	rivaroxaban (without LMWH)	LMWH/VKA				-
Einstein-DVT Evaluation, 2010 NCT	rivaroxaban (without LMWH)	LMWH/VKA		DOAC without heparin	Low risk of bias	suggesting
Einstein-PE Evaluation, 2012 NCT	rivaroxaban (without LMWH)	LMWH/VKA			Risk of bias	-
rosuvastatin
VanGogh extension, 2007 NCT	idraparinux	discontinuation				suggesting
tinzaparin
Romera, 2009	Tinzaparin	acenocoumarol			Risk of bias	suggesting
Hull, 2006	extended tinzaparin	standard treatment				negative
Hull, 2002	Tinzaparin	warfarin			Risk of bias	negative
Hull et al , 1992	Tinzaparin	unfractionated heparin				suggesting
warfarin
Schulman, 1995	6 months	1.5 months				suggesting
Pinede, 2001	3-6 months	1.5-3 months				negative
Wells (subgroup), 2005	tinzaparin	dalteparin				negative
PROLONG (Palareti), 2006 NCT	warfarin	discontinuation				suggesting
Levine, 1995	warfarin	discontinuation			Low risk of bias	suggesting
LAFIT (Kearon), 1999	warfarin	discontinuation				suggesting
Agnelli, 2001	warfarin	discontinuation				negative
Agnelli, 2003	warfarin	discontinuation				negative
PREVENT (Ridker), 2003	warfarin	discontinuation				suggesting
ELAET (Kearon), 2004	warfarin	discontinuation			Low risk of bias	negative
DURAC (Schulman), 1997	warfarin	discontinuation				suggesting
ximelagatran
THRIVE III, 2003	ximelagatran	discontinuation			Low risk of bias	suggesting
Schulman (subgroup), 2003	ximelagatran	placebo	patients with cancer			-
Fiessinger , 2005	ximelagatran	LMWH/VKA			Low risk of bias	-
THRIVE I, 2003	ximelagatran (without LMWH)	LMWH/VKA				-

antithrombotics systematic review meta-analysis network meta-analysis

Group by...

antithrombotics
systematic review meta-analysis network meta-analysis